Infliximab treatment maintains employability in XXXX with early @entity309 .

@entity1 @entity1500 @entity1499 @entity309
OBJECTIVE: To evaluate the impact of infliximab therapy on the employment status of @entity1 with early @entity309 ( @entity309 ). METHODS: @entity1499 ( @entity1500 )-naive @entity1 with active early @entity309 were randomly allocated to receive @entity1500 plus placebo or @entity1500 plus infliximab (3 mg/kg or 6 mg/kg) at weeks 0, 2, and 6 and then every 8 weeks through week 46. Data for @entity1 younger than age 65 years were included in the analyses. A @entity1 was categorized as employable if he or she was employed or felt well enough to work if a job were available. RESULTS: The change in actual employment was not significantly different between @entity1 receiving @entity1500 plus infliximab and those receiving @entity1500 plus placebo (0.5% versus 1.3%; P > 0.5). However, the proportion of @entity1 whose status changed from employable at baseline to unemployable at week 54 was smaller in the group receiving @entity1500 plus infliximab compared with that in the group receiving @entity1500 alone (8% versus 14%; P = 0.05). @entity1 who were treated with infliximab plus @entity1500 had a significantly greater likelihood of improvement rather than deterioration in employability (odds ratio 2.4; P < 0.001); this likelihood was not significantly greater in @entity1 receiving @entity1500 alone. The proportion of employed @entity1 who lost workdays during the trial was smaller in the @entity1500 plus infliximab group than in the @entity1500 -alone group (P = 0.010). CONCLUSION: The actual employment rates among @entity1 in the 2 treatment groups were not different. However, @entity1 with early @entity309 who were treated with @entity1500 plus infliximab had a higher probability of maintaining their employability compared with those who were treated with @entity1500 alone.
